Aspira Women's Health Inc.
Developer and commercializer of noninvasive, blood-based diagnostic tests for gynecologic diseases. The company combines protein and microRNA biomarker assays with data-driven algorithms, including deep neural networks, to produce risk-assessment scores used alongside imaging and clinical assessment. It conducts clinical studies, analytical validation, and publishes peer-reviewed results while pursuing an expanded pipeline addressing ovarian cancer and endometriosis.
Industries
Nr. of Employees
medium (51-250)
Aspira Women's Health Inc.
Patents
Products
Blood-based ovarian mass risk monitoring test using neural-network algorithm
A noninvasive blood test that combines protein biomarkers and patient variables with a deep-learning algorithm to provide longitudinal monitoring and negative-predictive-value–focused risk assessment for adnexal masses.
Reflex multivariate blood-based malignancy risk assessment for surgical candidates
A staged laboratory testing approach where an initial multivariate protein-based assay is performed and, for intermediate results, an automated reflex assay is executed to improve specificity prior to surgical planning.
Ova1
Proteomic in vitro diagnostic multivariate index assay approved by the FDA for clinical use in assessing ovarian cancer malignancy risk in women with pelvic masses when surgical intervention is planned.
Ova1Plus
An FDA-cleared blood test that combines multiple biomarkers to assess the risk of ovarian malignancy in women with adnexal masses planned for surgery with over 96% sensitivity.
OvaWatch
A non-invasive blood test for assessing ovarian cancer risk in women with benign or indeterminate adnexal masses demonstrating over 99% negative predictive value.
OVAinform
Next Generation Ovarian Cancer Risk Assessment. A promising new AI-powered blood test to aid in the identification of ovarian cancer in women diagnosed with an adnexal mass.
Blood-based ovarian mass risk monitoring test using neural-network algorithm
A noninvasive blood test that combines protein biomarkers and patient variables with a deep-learning algorithm to provide longitudinal monitoring and negative-predictive-value–focused risk assessment for adnexal masses.
Reflex multivariate blood-based malignancy risk assessment for surgical candidates
A staged laboratory testing approach where an initial multivariate protein-based assay is performed and, for intermediate results, an automated reflex assay is executed to improve specificity prior to surgical planning.
Ova1
Proteomic in vitro diagnostic multivariate index assay approved by the FDA for clinical use in assessing ovarian cancer malignancy risk in women with pelvic masses when surgical intervention is planned.
Ova1Plus
An FDA-cleared blood test that combines multiple biomarkers to assess the risk of ovarian malignancy in women with adnexal masses planned for surgery with over 96% sensitivity.
OvaWatch
A non-invasive blood test for assessing ovarian cancer risk in women with benign or indeterminate adnexal masses demonstrating over 99% negative predictive value.
OVAinform
Next Generation Ovarian Cancer Risk Assessment. A promising new AI-powered blood test to aid in the identification of ovarian cancer in women diagnosed with an adnexal mass.
Services
Provision of blood-based laboratory tests that quantify biomarker levels and generate diagnostic risk scores for use with imaging and clinical assessment.
Collaboration with clinical investigators and health systems to design and execute validation studies and publications assessing assay performance.
Provision of blood-based laboratory tests that quantify biomarker levels and generate diagnostic risk scores for use with imaging and clinical assessment.
Collaboration with clinical investigators and health systems to design and execute validation studies and publications assessing assay performance.
Expertise Areas
- Gynecologic diagnostic assay development
- Biomarker discovery and multivariate assay design
- Machine learning and neural-network-based diagnostics
- Clinical validation and longitudinal monitoring studies
Key Technologies
- Deep neural networks / deep learning
- Multivariate biomarker assays (protein + microRNA)
- Blood-based diagnostic assays
- Reflex testing workflows
News & Updates
Poster on association of patient-reported instrument (EHP-5) with noninvasive biomarkers in suspected endometriosis presented at NPWH conference.
Presentation on application of a deep neural network algorithm to provide additional information in assessment of adnexal masses indeterminate by imaging.
Company announced Q2 financial results and a webcast to discuss results and corporate update.
Peer-reviewed analytical validation of a deep neural network algorithm applied to blood-based biomarker data for ovarian cancer risk assessment.
Study detailing clinical performance of a neural network-derived multivariate assay for ongoing monitoring of ovarian cancer risk.
Publications analyzing cost-effectiveness and payer implications of multivariate assay testing compared to CA-125 and guideline-based triage.
Poster on association of patient-reported instrument (EHP-5) with noninvasive biomarkers in suspected endometriosis presented at NPWH conference.
Presentation on application of a deep neural network algorithm to provide additional information in assessment of adnexal masses indeterminate by imaging.
Company announced Q2 financial results and a webcast to discuss results and corporate update.
Peer-reviewed analytical validation of a deep neural network algorithm applied to blood-based biomarker data for ovarian cancer risk assessment.
Study detailing clinical performance of a neural network-derived multivariate assay for ongoing monitoring of ovarian cancer risk.
Publications analyzing cost-effectiveness and payer implications of multivariate assay testing compared to CA-125 and guideline-based triage.